LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

28.13 -0.53

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.88

Max

28.41

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-187M -136M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	9.117 66.845
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	-55.871
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+44.69% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	117M 1.7B
Ankstesnė atidarymo kaina	28.66
Ankstesnė uždarymo kaina	28.13

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-06 19:32; UTC

Įsigijimai, susijungimai, perėmimai

Diana Shipping Increases Offer to Acquire Genco -- Update

2026-03-06 17:44; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

2026-03-07 02:30; UTC

Svarbiausios naujienos

Iran War Is Kicking India When It's Already Down -- Barrons.com

2026-03-06 22:26; UTC

Svarbiausios naujienos

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

2026-03-06 22:07; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

2026-03-06 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-06 21:37; UTC

Uždarbis

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

2026-03-06 21:25; UTC

Svarbiausios naujienos

How The Iran War Impacts Ukraine. -- Barrons.com

2026-03-06 21:17; UTC

Uždarbis

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

2026-03-06 20:50; UTC

Uždarbis

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

2026-03-06 20:46; UTC

Uždarbis

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026-03-06 20:31; UTC

Svarbiausios naujienos

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

2026-03-06 20:18; UTC

Rinkos pokalbiai

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

2026-03-06 20:12; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

2026-03-06 19:10; UTC

Rinkos pokalbiai

Svarbiausios naujienos

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

2026-03-06 18:54; UTC

Rinkos pokalbiai

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

2026-03-06 18:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

2026-03-06 18:08; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 17:49; UTC

Rinkos pokalbiai

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

2026-03-06 17:46; UTC

Svarbiausios naujienos

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

2026-03-06 17:40; UTC

Rinkos pokalbiai

Uždarbis

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

2026-03-06 17:40; UTC

Uždarbis

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026-03-06 17:32; UTC

Rinkos pokalbiai

Svarbiausios naujienos

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

2026-03-06 17:28; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

2026-03-06 17:20; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-03-06 17:20; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

44.69% į viršų

12 mėnesių prognozė

Vidutinis 41.25 USD 44.69%

Aukščiausias 62 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.